Risk Prediction in Patients With Metabolic Dysfunction–Associated Steatohepatitis Using Natural Language Processing
Background and Aims: Metabolic dysfunction–associated steatohepatitis (MASH) is a highly heterogenous condition and a leading cause of end-stage liver disease. Understanding disease progression in real-world settings remains a major unmet need. We sought to define a real-world MASH cohort using natu...
Saved in:
Main Authors: | Jordan Guillot, Christopher Y.K. Williams, Shadera Azzam, Balu Bhasuran, Gail Fernandes, Boshu Ru, Joe Yang, Xiao Zhang, R. Ravi Shankar, Jin Ge, Vivek A. Rudrapatna |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2025-01-01
|
Series: | Gastro Hep Advances |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2772572325000883 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Letter to the editor on “Bariatric surgery reduces long-term mortality in patients with metabolic dysfunction-associated steatotic liver disease and cirrhosis”
by: Weixiong Zhu, et al.
Published: (2025-07-01) -
Association of estimated glucose disposal rate with risk of future metabolic dysfunction-associated steatotic liver disease and other chronic liver diseases: a prospective cohort study
by: Yan Li, et al.
Published: (2025-07-01) -
The Effect of Statin Therapy on Mortality in Adult Patients with Liver Cirrhosis: An Evidence-Based Case Report
by: Raksheeth Agarwal, et al.
Published: (2022-09-01) -
Phosphatidylethanol and ethyl glucuronide to categorize alcohol consumption in alcohol-related cirrhosis
by: Benedict T.K. Vanlerberghe, et al.
Published: (2025-08-01) -
Impact of myokines on chronic liver diseases: exploring the effects of metabolic dysfunction-associated steatotic liver disease (MASLD) on skeletal muscle. A narrative review
by: Francisco Aguirre, et al.
Published: (2025-07-01)